BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations-Reference-Cited by-同舟云学术

BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations

Published:2017-05-23 Issue:25 Volume:8 Page:39945-39962
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Deihimi Safoora¹²³⁴,Lev Avital¹²³,Slifker Michael⁵,Shagisultanova Elena³⁶,Xu Qifang²,Jung Kyungsuk⁷,Vijayvergia Namrata³,Ross Eric A.⁵⁸,Xiu Joanne⁹,Swensen Jeffrey⁹,Gatalica Zoran⁹,Andrake Mark²,Dunbrack Roland L.²,El-Deiry Wafik S.¹²³⁴

Affiliation:

1. Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, USA

2. Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA

3. Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

4. Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA, USA

5. Biostatistics and Bioinformatics Department, Fox Chase Cancer Center, Philadelphia, PA, USA

6. University of Colorado Denver Cancer Center, Denver, CO, USA

7. Department of Medicine, Fox Chase Cancer Center, Philadelphia, PA, USA

8. Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA, USA

9. Caris Life Science, Phoenix, AZ, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Coexisting germline variants of MLH1 and MSH6 in a patient with Lynch syndrome, endometrial cancer, and ovarian cancer;2024-02-07

2. Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study;Lung Cancer;2023-07

3. A Gene Therapy for Hereditary Nonpolyposis Colorectal Cancer using CRISPR-Cas9 Nickase;2023-06-22

4. Biomarkers for chemotherapy and drug resistance in the mismatch repair pathway;Clinica Chimica Acta;2023-04

5. Genetic alterations shaping tumor response to anti-EGFR therapies;Drug Resistance Updates;2022-09